Cargando…

Palonosetron as an anti-emetic and anti-nausea agent in oncology

Palonosetron (Aloxi(®), Onicit(®), Paloxi(®)) is a second-generation 5-HT(3) receptor antagonist (RA) with an extended half-life of ~40 hours and high binding affinity for the 5-HT(3) receptor that is markedly different from other 5-HT(3) RAs. Phase III trials demonstrate that a single dose of palon...

Descripción completa

Detalles Bibliográficos
Autor principal:	Aapro, Matti S
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387285/ https://www.ncbi.nlm.nih.gov/pubmed/18516316

Ejemplares similares

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Management of postoperative nausea and vomiting: focus on palonosetron
por: Muchatuta, Neil A, et al.
Publicado: (2009)

Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics
por: Perwitasari, D. A., et al.
Publicado: (2011)

Intravenous amisulpride: A safer and possibly effective anti-emetic for postoperative nausea and vomiting
por: Nair, Abhijit, et al.
Publicado: (2021)

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
por: Nilsson, Jonas, et al.
Publicado: (2022)

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
por: Bajetta, Emilio, et al.
Publicado: (2009)

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
por: Navari, Rudolph M
Publicado: (2009)

Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
por: Zhou, Michelle, et al.
Publicado: (2015)

Comparison of palonosetron with combined palonosetron and midazolam for preventing postoperative nausea and vomiting after laparoscopic cholecystectomy
por: Choi, Eun Kyung, et al.
Publicado: (2021)

Anti-emetics and cancer chemotherapy.
por: Leonard, R. C., et al.
Publicado: (1990)

Improved prophylaxis of postoperative nausea vomiting: Palonosetron a novel antiemetic
por: Shetti, Akshaya N., et al.
Publicado: (2014)

Assessment of Dog Owner Concern Regarding Peri-operative Nausea and Vomiting and Willingness to Pay for Anti-emetic Treatment
por: Kraus, Bonnie L. Hay, et al.
Publicado: (2019)

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
por: Aapro, Matti, et al.
Publicado: (2016)

Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
por: Lorusso, Vito
Publicado: (2016)

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

One‐Day Versus Three‐Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data‐Based Meta‐Analysis
por: Okada, Yuki, et al.
Publicado: (2019)

Anti-emetic Drugs for Prophylaxis of Postoperative Nausea and Vomiting After Craniotomy: An Updated Systematic Review and Network Meta-Analysis
por: Chen, Yijing, et al.
Publicado: (2020)

Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems
por: Zhong, Weixia, et al.
Publicado: (2021)

Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
por: Affronti, Mary Lou, et al.
Publicado: (2014)

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination
por: Janicki, Piotr K
Publicado: (2016)

Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials
por: Celio, Luigi, et al.
Publicado: (2012)

The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting
por: Park, Jung Woo, et al.
Publicado: (2012)

Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery
por: Liu, Qili, et al.
Publicado: (2017)

Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Efficacy of palonosetron in the management of postoperative nausea vomiting in oral and maxillofacial surgery
por: Rapolu, Keerthi, et al.
Publicado: (2022)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction
por: Aapro, Matti
Publicado: (2018)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
por: Aapro, Matti
Publicado: (2018)

The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting
por: Coyne, Joseph W.
Publicado: (2016)

Comparison of Palonosetron Versus Palonosetron and Dexamethasone for Prevention of Postoperative Nausea and Vomiting After Middle Ear Surgeries: A Randomized Controlled Study
por: Kumar, Kanhaiya, et al.
Publicado: (2022)

The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting
por: HUANG, JIAN, et al.
Publicado: (2013)

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy
por: Celio, Luigi, et al.
Publicado: (2015)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

Anti-emetic effects of thalidomide: Evidence, mechanism of action, and future directions
por: Andrews, Paul L.R., et al.
Publicado: (2022)

Comparison of efficacy of palonosetron-dexamethasone combination with palonosetron or dexamethasone alone for prophylaxis against post-operative nausea and vomiting in patients undergoing laparoscopic cholecystectomy
por: Chatterjee, Arindam, et al.
Publicado: (2017)

Cathodic adsorptive stripping voltammetry of an anti-emetic agent Granisetron in pharmaceutical formulation and biological matrix
por: Jain, Rajeev, et al.
Publicado: (2012)

Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
por: Iihara, Hirotoshi, et al.
Publicado: (2016)

Palonosetron: A novel approach to control postoperative nausea and vomiting in day care surgery
por: Bajwa, Sukhminderjit Singh, et al.
Publicado: (2011)

Different Doses of Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Children Undergoing Strabismus Surgery
por: Bicer, Cihangir, et al.
Publicado: (2012)

Palonosetron, Ondansetron, and Granisetron for antiemetic prophylaxis of postoperative nausea and vomiting - A comparative evaluation
por: Gupta, Kumkum, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_agchjlh3r77ef8d07t01kev2tu